Please try another search
Scopus BioPharma Inc., a clinical-stage biopharmaceutical company, focuses on developing transformational therapeutics targeting serious diseases with unmet medical needs. It offers Duet Platform, which consists of signal transducer and activator of transcription 3 (STAT3), a master immune checkpoint inhibitor and toll-like receptor 9 (TLR9), as well as includes CpG-STAT3ASO (DUET-02), CpG-STAT3siRNA (DUET-01), and CpG-STAT3decoy (DUET-03); and that develops a suite of bifunctional oligonucleotides that activate antigen-presenting cells (APCs) in the tumor microenvironment that alleviates tumor immunosuppression to jump-start T cell-mediated immune responses. The company is also developing DUET-01, as a monotherapy targeting B-cell non-Hodgkin lymphoma; DUET-02 that provides systemic delivery for treatment of solid tumors comprising prostate or kidney cancers; and DUET-03, which targets the actual STAT3 transcription factor protein. Scopus BioPharma Inc. has licensing agreements with the City of Hope, National Institutes of Health Program, and The Hebrew University of Jerusalem. The company was formerly known as Project18 Inc. and changed its name to Scopus BioPharma Inc. in December 2017. Scopus BioPharma Inc. was incorporated in 2017 and is headquartered in New York, New York.
Name | Age | Since | Title |
---|---|---|---|
Joshua R. Lamstein | 51 | 2017 | Chairman |
George Kunos | - | 2017 | Member of Scientific Advisory Board |
Yossi Tam | - | 2018 | Member of Scientific Advisory Board |
David A. Buckel | 60 | 2020 | Independent Director |
Yair Levy | - | 2017 | Member of Scientific Advisory Board |
David Weild | 65 | 2020 | Independent Director |
Aharon Schwartz | 79 | 2018 | Member of Scientific Advisory Board |
Robert Spiera | - | 2017 | Member of Scientific Advisory Board |
Hua E. Yu | - | - | Member of Scientific Advisory Board |
Marcin Kortylewski | - | - | Member of Scientific Advisory Board |
Ira Scott Greenspan | 64 | 2017 | Senior Advisor & Director |
Robert J. Gibson | - | 2017 | Vice Chairman, Secretary & Treasurer |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review